Cellectis (NASDAQ:CLLS) Upgraded at StockNews.com

StockNews.com upgraded shares of Cellectis (NASDAQ:CLLS) from a hold rating to a buy rating in a report issued on Friday morning.

Cellectis Stock Up 1.3 %

Shares of CLLS stock opened at $1.53 on Friday. The stock’s fifty day moving average price is $1.33 and its 200 day moving average price is $1.62. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.78 and a quick ratio of 1.78. Cellectis has a 1-year low of $1.10 and a 1-year high of $3.38. The company has a market cap of $85.04 million, a price-to-earnings ratio of -1.18 and a beta of 3.22.

Cellectis (NASDAQ:CLLS) last posted its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($0.22). The company had revenue of $33.22 million for the quarter, compared to analyst estimates of $5.90 million. Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. On average, research analysts expect that Cellectis will post -0.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cellectis

A number of large investors have recently made changes to their positions in CLLS. Wells Fargo & Company MN lifted its position in Cellectis by 103.4% during the 4th quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 12,500 shares during the period. Millennium Management LLC acquired a new position in shares of Cellectis in the fourth quarter valued at about $962,000. Finally, B Group Inc. purchased a new position in shares of Cellectis in the fourth quarter worth about $5,547,000. 63.90% of the stock is owned by hedge funds and other institutional investors.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.